ABEO earnings call for the period ending March 31, 2019.
News & Analysis: Abeona Therapeutics
ABEO earnings call for the period ending December 31, 2018.
Small market caps. Big opportunities.
A clinical trial update for AB-102 didn't go far enough.
Can these red-hot biotech stocks keep the momentum going?
Positive clinical trial data from a single patient sends shares soaring.
The red-hot gene therapy start-up took a big step towards its first new drug application.
An analyst started coverage at a buy, but there's more that long-term investors should be focused on.
Abeona, Sangamo, and Juno ride the huge wave resulting from Gilead Sciences' acquisition of Kite Pharma.
An FDA "breakthrough therapy" designation for Abeona's gene therapy sent shares of the company higher, but investors should focus on the bigger picture.